These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15061204)

  • 1. Lack of prognostic significance of BCL2 and p53 protein overexpression in elderly patients with diffuse large B-cell non-Hodgkin's lymphoma: results from a population-based non-Hodgkin's lymphoma registry.
    Maartense E; Kramer MH; le Cessie S; Kluin-Nelemans JC; Kluin PM; Snijder S; Noordijk EM
    Leuk Lymphoma; 2004 Jan; 45(1):101-7. PubMed ID: 15061204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.
    Kramer MH; Hermans J; Parker J; Krol AD; Kluin-Nelemans JC; Haak HL; van Groningen K; van Krieken JH; de Jong D; Kluin PM
    J Clin Oncol; 1996 Jul; 14(7):2131-8. PubMed ID: 8683246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.
    Chatzitolios A; Venizelos I; Tripsiannis G; Anastassopoulos G; Papadopoulos N
    Ann Hematol; 2010 Sep; 89(9):889-96. PubMed ID: 20352431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
    Kim S; Nam SJ; Kwon D; Kim H; Lee E; Kim TM; Heo DS; Park SH; Kim CW; Jeon YK
    BMC Cancer; 2016 Jun; 16():363. PubMed ID: 27286976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of Bcl2 and p53 in Hodgkin lymphoma: A systematic review and meta-analysis.
    Travaglino A; Russo D; Varricchio S; Picardi M; Mascolo M
    Pathol Res Pract; 2021 Mar; 219():153370. PubMed ID: 33618247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
    Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
    Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
    Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM
    Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma.
    Pătraşcu AM; Rotaru I; Olar L; Pătraşcu Ş; Ghiluşi MC; NeamŢu SD; Nacea JG; Gluhovschi A
    Rom J Morphol Embryol; 2017; 58(3):837-843. PubMed ID: 29250662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
    Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
    Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.
    Borovecki A; Korać P; Nola M; Ivanković D; Jaksić B; Dominis M
    Croat Med J; 2008 Oct; 49(5):625-35. PubMed ID: 18925696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
    Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
    Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.
    Makino K; Nakamura H; Shinojima N; Kuroda JI; Yano S; Mikami Y; Mukasa A
    J Neurooncol; 2018 Oct; 140(1):115-121. PubMed ID: 29968039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of P53 Expression on Prognosis of Patients with Double Expressor Lymphoma].
    Ding X; Hou SL; Li YQ; Li X; Li L; Lian K; Wang GG; Wu XB; Zhang ZH; Liu H; Wang YQ; Zhang QH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1504-1514. PubMed ID: 31607305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma.
    Llanos M; Alvarez-Argüelles H; Alemán R; Oramas J; Diaz-Flores L; Batista N
    Med Oncol; 2001; 18(1):15-22. PubMed ID: 11778965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma.
    Inagaki H; Banno S; Wakita A; Ueda R; Eimoto T
    Mod Pathol; 1999 May; 12(5):546-52. PubMed ID: 10349995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein expression of bax, bcl-2, and p53 in patients with non-Hodgkin's gastric lymphoma: prognostic significance.
    Charalambous GK; Gomatos IP; Konstadoulakis MM; Messaris EG; Manouras AJ; Apostolou AE; Leandros EA; Karayannis MK; Androulakis GA
    World J Surg; 2000 May; 24(5):608-14. PubMed ID: 10787085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma.
    Møller MB; Nielsen O; Pedersen NT
    Histopathology; 2002 Oct; 41(4):322-30. PubMed ID: 12383214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
    Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
    Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of P53 and bcl-2 proteins in T-cell lymphoblastic lymphoma: prognostic implications.
    Naresh KN; Banavali SD; Bhatia KG; Magrath I; Soman CS; Advani SH
    Leuk Lymphoma; 2002 Feb; 43(2):333-7. PubMed ID: 11999565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.